Debt-to-equity in % of Spyre Therapeutics, Inc. from Q3 2016 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Spyre Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q3 2016 to Q3 2025.
  • Spyre Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 16.2 %, a 45.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Spyre Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 16.2 -13.7 -45.7% 30 Sep 2025
Q2 2025 19.9 -40.8 -67.3% 30 Jun 2025
Q1 2025 19.6 +427 31 Mar 2025
Q4 2024 23.9 +199 31 Dec 2024
Q3 2024 29.9 +127 30 Sep 2024
Q2 2024 60.7 +629 30 Jun 2024
Q1 2024 -407 -444 -1213% 31 Mar 2024
Q4 2023 -175 -209 -619% 31 Dec 2023
Q3 2023 -97.3 -129 -408% 30 Sep 2023
Q2 2023 -568 -597 -2042% 30 Jun 2023
Q1 2023 36.6 +8.64 +30.9% 31 Mar 2023
Q4 2022 33.7 +5.55 +19.7% 31 Dec 2022
Q3 2022 31.6 +7.58 +31.5% 30 Sep 2022
Q2 2022 29.2 +8.24 +39.2% 30 Jun 2022
Q1 2022 27.9 +9.52 +51.7% 31 Mar 2022
Q4 2021 28.2 +10.4 +58.4% 31 Dec 2021
Q3 2021 24.1 +2.31 +10.6% 30 Sep 2021
Q2 2021 21 -4.69 -18.3% 30 Jun 2021
Q1 2021 18.4 -11.1 -37.6% 31 Mar 2021
Q4 2020 17.8 -2.88 -13.9% 31 Dec 2020
Q3 2020 21.7 +5.02 +30% 30 Sep 2020
Q2 2020 25.7 +11.9 +85.6% 30 Jun 2020
Q1 2020 29.5 +18.2 +160% 31 Mar 2020
Q4 2019 20.7 +8.57 +70.9% 31 Dec 2019
Q3 2019 16.7 +5.71 +51.9% 30 Sep 2019
Q2 2019 13.8 +3.59 +35% 30 Jun 2019
Q1 2019 11.4 +1.39 +14% 31 Mar 2019
Q4 2018 12.1 +3.51 +40.9% 31 Dec 2018
Q3 2018 11 +3.57 +48% 30 Sep 2018
Q2 2018 10.2 +3.64 +55.1% 30 Jun 2018
Q1 2018 9.95 +4.07 +69.2% 31 Mar 2018
Q4 2017 8.58 +0.07 +0.82% 31 Dec 2017
Q3 2017 7.44 -7.18 -49.1% 30 Sep 2017
Q2 2017 6.61 30 Jun 2017
Q1 2017 5.88 31 Mar 2017
Q4 2016 8.5 31 Dec 2016
Q3 2016 14.6 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.